Vaxart Posts $72.4M in Q3 Revenue, a Massive Jump for the Micro-Cap
VXRT is trading near its 52-week low of $0.32 (14% above the low).
Summary
Vaxart reported third-quarter revenue of $72.4M, an extraordinary figure for a company with a market cap under $90M and a stock at $0.365, but the quarter also brought a loss of $8.14M. That revenue dwarfs the scale implied by its valuation and follows Q1 2026, when the company reported profitability and said it had resolved its going concern warning. The number is the whole story here: if it reflects real, recurring revenue rather than a one-time item, it resets the entire thesis for a company that has been living off a $49.7M at-the-market offering and a $300M shelf. The wire carried only the top-line figure, so the composition of that revenue and any guidance will decide whether this holds.
At the time of this announcement, VXRT was trading at $0.37 on OTC in the Life Sciences sector, with a market capitalization of approximately $88.6M. The 52-week trading range was $0.32 to $0.84. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.